Innovations in RNA Interference and Biotech Entrepreneurship

This chapter explores the evolution of RNA interference (RNAi) technology and its potential future impact on biotechnology, comparing it to monoclonal antibodies development. Discussions focus on the entrepreneurial spirit within smaller biotech startups and their advantages over larger pharmaceutical companies, emphasizing innovation and product pipelines. The chapter also highlights the significant role of venture capitalists, recent advancements like AI in protein prediction, and the importance of solid clinical data for biotech companies looking to go public.